172 related articles for article (PubMed ID: 31340773)
1. High baseline Tie1 level predicts poor survival in metastatic breast cancer.
Tiainen L; Korhonen EA; Leppänen VM; Luukkaala T; Hämäläinen M; Tanner M; Lahdenperä O; Vihinen P; Jukkola A; Karihtala P; Aho S; Moilanen E; Alitalo K; Kellokumpu-Lehtinen PL
BMC Cancer; 2019 Jul; 19(1):732. PubMed ID: 31340773
[TBL] [Abstract][Full Text] [Related]
2. Tie1 controls angiopoietin function in vascular remodeling and inflammation.
Korhonen EA; Lampinen A; Giri H; Anisimov A; Kim M; Allen B; Fang S; D'Amico G; Sipilä TJ; Lohela M; Strandin T; Vaheri A; Ylä-Herttuala S; Koh GY; McDonald DM; Alitalo K; Saharinen P
J Clin Invest; 2016 Sep; 126(9):3495-510. PubMed ID: 27548530
[TBL] [Abstract][Full Text] [Related]
3. Tie1 regulates the Tie2 agonistic role of angiopoietin-2 in human lymphatic endothelial cells.
Song SH; Kim KL; Lee KA; Suh W
Biochem Biophys Res Commun; 2012 Mar; 419(2):281-6. PubMed ID: 22342979
[TBL] [Abstract][Full Text] [Related]
4. Effects of angiopoietins-1 and -2 on the receptor tyrosine kinase Tie2 are differentially regulated at the endothelial cell surface.
Hansen TM; Singh H; Tahir TA; Brindle NP
Cell Signal; 2010 Mar; 22(3):527-32. PubMed ID: 19922791
[TBL] [Abstract][Full Text] [Related]
5. High-circulating Tie2 Is Associated With Pathologic Complete Response to Chemotherapy and Antiangiogenic Therapy in Breast Cancer.
Makhoul I; Griffin RJ; Siegel E; Lee J; Dhakal I; Raj V; Jamshidi-Parsian A; Klimberg S; Hutchins LF; Kadlubar S
Am J Clin Oncol; 2016 Jun; 39(3):248-54. PubMed ID: 24577164
[TBL] [Abstract][Full Text] [Related]
6. Angiogenesis- and Hypoxia-Associated Proteins as Early Indicators of the Outcome in Patients with Metastatic Breast Cancer Given First-Line Bevacizumab-Based Therapy.
Lam SW; Nota NM; Jager A; Bos MM; van den Bosch J; van der Velden AM; Portielje JE; Honkoop AH; van Tinteren H; Boven E;
Clin Cancer Res; 2016 Apr; 22(7):1611-20. PubMed ID: 26823602
[TBL] [Abstract][Full Text] [Related]
7. Neuropilin-1 and placental growth factor as prognostic factors in metastatic breast cancer.
Mäenpää N; Tiainen L; Hämäläinen M; Luukkaala T; Tanner M; Lahdenperä O; Vihinen P; Karihtala P; Kellokumpu-Lehtinen PL; Moilanen E; Jukkola A
BMC Cancer; 2024 Mar; 24(1):331. PubMed ID: 38468231
[TBL] [Abstract][Full Text] [Related]
8. Tie1: an orphan receptor provides context for angiopoietin-2/Tie2 signaling.
Mueller SB; Kontos CD
J Clin Invest; 2016 Sep; 126(9):3188-91. PubMed ID: 27548526
[TBL] [Abstract][Full Text] [Related]
9. Enhanced expression of angiopoietin-2 and the Tie2 receptor but not angiopoietin-1 or the Tie1 receptor in a rat model of myocardial infarction.
Shyu KG; Liang YJ; Chang H; Wang BW; Leu JG; Kuan P
J Biomed Sci; 2004; 11(2):163-71. PubMed ID: 14966366
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.
von Minckwitz G; Puglisi F; Cortes J; Vrdoljak E; Marschner N; Zielinski C; Villanueva C; Romieu G; Lang I; Ciruelos E; De Laurentiis M; Veyret C; de Ducla S; Freudensprung U; Srock S; Gligorov J
Lancet Oncol; 2014 Oct; 15(11):1269-78. PubMed ID: 25273342
[TBL] [Abstract][Full Text] [Related]
11. Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer.
Banys-Paluchowski M; Fehm T; Janni W; Aktas B; Fasching PA; Kasimir-Bauer S; Milde-Langosch K; Pantel K; Rack B; Riethdorf S; Solomayer EF; Witzel I; Müller V
BMC Cancer; 2018 May; 18(1):541. PubMed ID: 29739347
[TBL] [Abstract][Full Text] [Related]
12. VEGF-A levels in bevacizumab-treated breast cancer patients: a systematic review and meta-analysis.
Santos LV; Cruz MR; Lopes Gde L; Lima JP
Breast Cancer Res Treat; 2015 Jun; 151(3):481-9. PubMed ID: 25947646
[TBL] [Abstract][Full Text] [Related]
13. Effect of aging and cardiovascular risk factors on receptor Tie1 expression in human erectile tissue.
Fonseca J; Tomada N; Magalhães A; Rodrigues AR; Gouveia AM; Neves D
J Sex Med; 2015 Apr; 12(4):876-86. PubMed ID: 25487286
[TBL] [Abstract][Full Text] [Related]
14. Expression and function of Angiopoietins and their tie receptors in human basophils and mast cells.
Prevete N; Staiano RI; Granata F; Detoraki A; Necchi V; Ricci V; Triggiani M; De Paulis A; Marone G; Genovese A
J Biol Regul Homeost Agents; 2013; 27(3):827-39. PubMed ID: 24152847
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial.
Cameron D; Brown J; Dent R; Jackisch C; Mackey J; Pivot X; Steger GG; Suter TM; Toi M; Parmar M; Laeufle R; Im YH; Romieu G; Harvey V; Lipatov O; Pienkowski T; Cottu P; Chan A; Im SA; Hall PS; Bubuteishvili-Pacaud L; Henschel V; Deurloo RJ; Pallaud C; Bell R
Lancet Oncol; 2013 Sep; 14(10):933-42. PubMed ID: 23932548
[TBL] [Abstract][Full Text] [Related]
16. Preclinical validation of a novel metastasis-inhibiting Tie1 function-blocking antibody.
Singhal M; Gengenbacher N; La Porta S; Gehrs S; Shi J; Kamiyama M; Bodenmiller DM; Fischl A; Schieb B; Besemfelder E; Chintharlapalli S; Augustin HG
EMBO Mol Med; 2020 Jun; 12(6):e11164. PubMed ID: 32302470
[TBL] [Abstract][Full Text] [Related]
17. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
Gianni L; Romieu GH; Lichinitser M; Serrano SV; Mansutti M; Pivot X; Mariani P; Andre F; Chan A; Lipatov O; Chan S; Wardley A; Greil R; Moore N; Prot S; Pallaud C; Semiglazov V
J Clin Oncol; 2013 May; 31(14):1719-25. PubMed ID: 23569311
[TBL] [Abstract][Full Text] [Related]
18. Low Plasma IL-8 Levels During Chemotherapy Are Predictive of Excellent Long-Term Survival in Metastatic Breast Cancer.
Tiainen L; Hämäläinen M; Luukkaala T; Tanner M; Lahdenperä O; Vihinen P; Jukkola A; Karihtala P; Moilanen E; Kellokumpu-Lehtinen PL
Clin Breast Cancer; 2019 Aug; 19(4):e522-e533. PubMed ID: 31029558
[TBL] [Abstract][Full Text] [Related]
19. Interaction between Tie receptors modulates angiogenic activity of angiopoietin2 in endothelial progenitor cells.
Kim KL; Shin IS; Kim JM; Choi JH; Byun J; Jeon ES; Suh W; Kim DK
Cardiovasc Res; 2006 Dec; 72(3):394-402. PubMed ID: 17054925
[TBL] [Abstract][Full Text] [Related]
20. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial.
Gligorov J; Doval D; Bines J; Alba E; Cortes P; Pierga JY; Gupta V; Costa R; Srock S; de Ducla S; Freudensprung U; Mustacchi G
Lancet Oncol; 2014 Nov; 15(12):1351-60. PubMed ID: 25273343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
